Bristol-Myers Squibb (BMY) has had a noticeable run on the stock market with a 7.6% increase over a five-day streak, arguably due to positive evaluations and drug approvals. Notably, BMY's valuation has been reassessed following a
15.6% jump in share price, with some arguing that this makes the stock a bargain. Indeed, several investors have
increased their holdings, including Norges Bank, Skandinaviska Enskilda Banken AB publ, and Grantham Mayo Van Otterloo & Co. LLC. BMY received a 'Hold' rating from several brokerages, indicating a neutral outlook. Despite the surge, the company experienced a
$6.6B one-off loss, posing a challenge. Meanwhile, Texas filed a
lawsuit against BMY, alleging cover-up of the ineffectiveness of their blood thinner Plavix. Regarding potential growth, BMY has gained
EU approval for Breyanzi in treating Mantle Cell Lymphoma, which could significantly boost its market presence. The company is set to participate in Citi’s 2025 Global Healthcare Conference and host an investor event focused on hematology.
Bristol-Myers Squibb BMY News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Sat, 29 Nov 2025 14:38:43 GMT -
Rating 7
- Innovation 3
- Information 7
- Rumor -6
